(Q37848142)

24 August 2017

1 reference

title

Drug and dietary interactions of warfarin and novel oral anticoagulants: an update (English)

1 reference

24 August 2017

1 reference

1 reference

1 reference

Edith Nutescu

1

1 reference

24 August 2017

Ittiporn Chuatrisorn

series ordinal

2

1 reference

24 August 2017

Erika Hellenbart

series ordinal

3

1 reference

24 August 2017

publication date

1 April 2011

1 reference

Journal of Thrombosis and Thrombolysis

24 August 2017

published in

1 reference

24 August 2017

volume

31

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

326-343

1 reference

Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Surveillance of prescription drug-related mortality using death certificate data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Systematic overview of warfarin and its drug and food interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Impact of preemptive warfarin dose reduction on anticoagulation after initiation of trimethoprim-sulfamethoxazole or levofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Spinal epidural haematoma as a result of warfarin/fluconazole drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Single-dose fluconazole for vulvovaginal candidiasis: impact on prothrombin time in women taking warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Intracerebral hemorrhage secondary to a warfarin-metronidazole interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Potentiation of warfarin anticoagulant activity by miconazole oral gel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Interaction between warfarin and topical miconazole cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Miconazole oral gel and drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Hyperprothrombinemia as a Result of a Possible Warfarin and Intravaginal Miconazole Interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Voriconazole potentiates warfarin‐induced prothrombin time prolongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Indeterminable international normalized ratio with concurrent use of warfarin and gatifloxacin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Anticoagulation-related outcomes in patients receiving warfarin after starting levofloxacin or gatifloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Retrospective assessment of potential interaction between levofloxacin and warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Ciprofloxacin prolonged-release tablets do not affect warfarin pharmacokinetics and pharmacodynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Interactions between warfarin and three commonly prescribed fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Further evidence of a clinically significant levofloxacin-warfarin interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Enhanced hypoprothrombinemia with warfarin due to azithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Azithromycin and warfarin interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Drug interactions with antiretrovirals and warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Possible antiretroviral therapy-warfarin drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Warfarin-antiretroviral interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Need for increased dose of warfarin in HIV patients taking nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Potential interaction involving warfarin and ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Interaction between lopinavir/ritonavir and warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Rosuvastatin-warfarin drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Probable warfarin-simvastatin interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Possible warfarin interaction with menthol cough drops

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Probable warfarin interaction with menthol cough drops

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Potential interactions between complementary/alternative products and conventional medicines in a Medicare population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Prevalence of use and the risk of adverse effects associated with complementary and alternative medicine in a cohort of patients receiving warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Potential interactions between prescription drugs and complementary and alternative medicines among patients in the emergency department

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Possible interaction between warfarin and cranberry juice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Elevated International Normalized Ratio after concurrent ingestion of cranberry sauce and warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

The absence of an interaction between warfarin and cranberry juice: a randomized, double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Effect of high-dose cranberry juice on the pharmacodynamics of warfarin in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Cranberry does not affect prothrombin time in male subjects on warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Cranberry juice and warfarin: when bad publicity trumps science

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Green tea may inhibit warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Probable antagonism of warfarin by green tea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Apixaban metabolism and pharmacokinetics after oral administration to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Interaction of doxycycline and warfarin: an enhanced anticoagulant effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Moxifloxacin and warfarin: additional evidence for a clinically relevant interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Interaction between gemfibrozil and warfarin: case report and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Antidepressants, warfarin, and the risk of hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Probable interaction between warfarin and marijuana smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Increased anticoagulant activity of warfarin used in combination with doxifluridine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Effect of oxolamine on anticoagulant effect of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Warfarin and its interactions with foods, herbs and other dietary supplements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

New oral anticoagulants: a practical guide for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-011-0561-1

Warfarin and miconazole oral gel interactions: analysis and therapy recommendations based on clinical data and a pharmacokinetic model.

21 January 2018

1 reference

12 December 2020

The stereoselective interaction of warfarin and metronidazole in man

1 reference

12 December 2020

Miconazole-warfarin interaction: increased INR.

1 reference

12 December 2020

The safety of levofloxacin in patients on warfarin

1 reference

12 December 2020

Co-ingestion of herbal medicines and warfarin.

1 reference

12 December 2020

Co-trimoxazole and warfarin: case report of an interaction

1 reference

12 December 2020

A significant interaction between metronidazole and warfarin

1 reference

12 December 2020

The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements.

1 reference

12 December 2020

Hospital admission due to warfarin potentiation by TMP-SMX.

1 reference

12 December 2020

Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies

1 reference

12 December 2020

Apixaban, an oral, direct inhibitor of activated Factor Xa.

1 reference

12 December 2020

Interaction between warfarin and levofloxacin: case series

1 reference

12 December 2020

Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers

1 reference

12 December 2020

Comment: TMP/SMX--warfarin interaction

1 reference

12 December 2020

Potentiation of warfarin action by miconazole oral gel

1 reference

12 December 2020

Venous thromboembolic disease in the HIV-infected patient.

1 reference

12 December 2020

Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding

1 reference

12 December 2020

Interaction between warfarin and cranberry juice

1 reference

12 December 2020

Fluconazole-warfarin interaction

1 reference

12 December 2020

Derangement of warfarin anticoagulation by miconazole oral gel

1 reference

12 December 2020

A systematic review and economic evaluation of statins for the prevention of coronary events.

1 reference

12 December 2020

Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug-drug and drug-disease interactions

1 reference

12 December 2020

Interaction between miconazole oral gel (Daktarin) and warfarin

1 reference

12 December 2020

Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium

1 reference

12 December 2020

Influence of indinavir and ritonavir on warfarin anticoagulant activity

1 reference

12 December 2020

Retrospective evaluation of a possible interaction between warfarin and levofloxacin

1 reference

12 December 2020

DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles

1 reference

12 December 2020

Potential interaction between azithromycin and warfarin

1 reference

12 December 2020

Possible potentiation of warfarin by fluconazole

1 reference

12 December 2020

Intraocular hemorrhages due to warfarin fluconazole drug interaction in a patient with presumed Candida endophthalmitis.

1 reference

12 December 2020

Possible increased anticoagulation effect of warfarin induced by azithromycin

1 reference

12 December 2020

Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict

1 reference

12 December 2020

Warfarin-miconazole interaction

1 reference

12 December 2020

Trends in use of complementary and alternative medicine by US adults: 1997-2002.

1 reference

12 December 2020

Drug interaction between co-trimoxazole and warfarin

1 reference

12 December 2020

Ritonavir and warfarin interaction

1 reference

12 December 2020

Drug-botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals

1 reference

12 December 2020

Topical use of miconazole antifungal oral gel on warfarinized patients: a word of caution

1 reference

12 December 2020

Utilization of complementary and alternative medicine by United States adults: results from the 1999 national health interview survey

1 reference

12 December 2020

Increased hypoprothrombinemic effect of warfarin possibly induced by azithromycin

1 reference

12 December 2020

Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic studies of acute interaction between warfarin enantiomers and metronidazole in rats

1 reference

12 December 2020

Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials

1 reference

12 December 2020

Clinical Pharmacology of Direct and Indirect Factor Xa Inhibitors

1 reference

12 December 2020

Warfarin--indications, risks and drug interactions.

1 reference

12 December 2020

Tea and coffee brews are not dietary sources of vitamin K-1 (phylloquinone)

1 reference

12 December 2020

Suspected trimethoprim/sulfamethoxazole-induced hypoprothrombinemia

1 reference

12 December 2020

The mechanism of action of rivaroxaban – an oral, direct Factor Xa inhibitor – compared with other anticoagulants

1 reference

12 December 2020

Interaction between warfarin and miconazole oral gel

1 reference

12 December 2020

Interaction of duloxetine and warfarin causing severe elevation of international normalized ratio

1 reference

12 December 2020

Case report: potentiation of warfarin by fluconazole

1 reference

12 December 2020

Potentiation of warfarin's hypoprothrombinemic effect with miconazole vaginal suppositories

1 reference

12 December 2020

Miconazole oral gel potentiates warfarin anticoagulant activity

1 reference

12 December 2020

Warfarin and cranberry juice: an interaction?

1 reference

12 December 2020

Hypoprothrombinemia during concomitant therapy with warfarin and saquinavir

1 reference

12 December 2020

10.1007/S11239-011-0561-1

Identifiers

DOI

1 reference

24 August 2017

1 reference